Pluri (PLUR) Ownership - Who owns Pluri?

Key Takeaways

• Pluri Inc. (PLUR) is an Israel-based biotechnology company that develops cell-based products and cell therapies using a proprietary three-dimensional (3D) cell-expansion platform.
• The company was incorporated in 2001 and was formerly known as Pluristem Therapeutics Inc. before renaming to Pluri Inc. in July 2022; it is headquartered in Haifa, Israel.
• Its business spans regenerative medicine, immunotherapy, contract manufacturing services (PluriCDMO), regenerative aesthetics, food technology, and agricultural technology.
• Key therapeutic candidates include PLX-PAD and PLX-R18, both derived from placental cells, as well as an allogeneic MAIT cell immunotherapy platform targeting solid tumors.
• As a clinical-stage and early-commercialization company, Pluri carries significant execution, regulatory, and capital-raising risks.

Introduction

Pluri Inc. is a biotechnology company that researches, develops, and manufactures cell-based products and cell therapeutics for applications across healthcare, food, and agriculture. Investors follow the stock because it sits at the intersection of several emerging fields, including regenerative medicine, cultivated meat, and cell-cultured coffee and cacao. The company's distinctive position comes from a single underlying technology: a proprietary three-dimensional (3D) cell-expansion platform designed to grow large quantities of cells efficiently and at scale.

Main Profile

Pluri was incorporated in 2001 in Nevada, with its primary operations conducted through its Israeli subsidiary, Pluri Biotech Ltd. The company is headquartered in Haifa, Israel, and its shares trade on the Nasdaq under the ticker PLUR. It was previously named Pluristem Therapeutics Inc. before adopting the Pluri Inc. name in July 2022.

The company's core asset is its 3D cell-expansion technology, which supports the manufacturing of cells in industrial quantities under Good Manufacturing Practice (GMP) standards. Around this platform, Pluri has organized several distinct business lines:

• Cell therapy and regenerative medicine: Pluri develops placenta-based cell therapy candidates. PLX-PAD is composed of maternal mesenchymal stromal cells and has been studied for indications such as muscle recovery following hip-fracture surgery and critical limb ischemia. PLX-R18 is composed of fetal MSC-like cells and has been explored for hematologic complications, including recovery after bone marrow transplantation.
• Immunotherapy: In 2024, Pluri launched a platform based on allogeneic MAIT cells isolated from the human placenta, aimed at treating solid tumors.
• PluriCDMO: Launched in 2024, this contract development and manufacturing organization (CDMO) division offers cell-manufacturing services to pharmaceutical and biotechnology companies, from preclinical development through commercialization.
• Regenerative aesthetics: Through its subsidiary CellaV Health and Aesthetics Ltd., Pluri develops cell-derived ingredients and aesthetic products.
• FoodTech: Pluri holds majority interests in Ever After Foods (cultivated meat technology), Coffeesai (cell-cultured coffee), and Kokomodo (cell-cultured cacao and cocoa-derived ingredients).
• AgTech: The company pursues proof-of-concept collaborations applying its cell-expansion technology to agriculture, including work with ICL Group.

This diversified structure means Pluri's business model combines early-stage biotech research and development with emerging revenue opportunities from manufacturing services and food technology. The company operates in a competitive and rapidly evolving landscape, competing against both established pharmaceutical and agricultural companies and other biotechnology startups.

Why Investors Follow PLUR

Pluri attracts attention because a single technology platform is applied across multiple potentially large markets. Its cell-expansion process is designed to produce cells in large volumes, which the company argues could improve the cost and scalability of cell-based products. This platform approach underpins its therapeutic pipeline, its contract manufacturing services, and its ventures into cultivated meat and plant-based ingredients.

Investors also follow the company for its exposure to long-term trends such as an aging global population, the growth of regenerative medicine, and the search for more sustainable food-production methods. The company's intellectual property portfolio, which includes numerous issued patents, and its GMP-compliant manufacturing capabilities are additional factors that draw interest. Its partnerships and joint-venture structure allow Pluri to pursue commercialization across industries while sharing development costs with collaborators.

Risks and Important Considerations

Investing in Pluri carries substantial risks typical of clinical-stage biotechnology and early-stage food-technology companies. Its lead therapeutic candidates remain in clinical development and have not yet received broad regulatory approval, meaning future commercialization is uncertain. The company's financial profile reflects a business that is still building revenue, and it may require additional capital to fund its operations and research programs.

Pluri also faces intense competition from companies with greater financial resources and more established commercial infrastructure. Its diversified strategy spans industries with different regulatory frameworks, which can increase operational complexity and execution risk. Food-tech ventures such as cultivated meat and cell-cultured coffee remain early-stage markets where consumer demand, regulatory pathways, and cost competitiveness are still developing. As with all biotechnology companies, clinical trial outcomes, regulatory decisions, and the ability to secure partnerships and funding can significantly affect the business.

AI Screener

For investors seeking to discover and evaluate opportunities like Pluri, Tickeron's AI Screener offers an AI-powered stock and ETF discovery platform. It helps traders and investors filter thousands of securities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable criteria. By screening across these dimensions, users can efficiently identify ideas that match their own investment strategies. Explore the AI Screener to refine your research process.

Conclusion

Pluri Inc. is a distinctive biotechnology company that has built its strategy around a proprietary 3D cell-expansion platform and applies it across healthcare, food, and agriculture. Its position at the convergence of regenerative medicine, immunotherapy, and food technology makes it relevant to investors interested in long-horizon, science-driven growth themes. At the same time, its clinical-stage pipeline, emerging revenue base, and multi-industry ambitions mean the company's outlook depends heavily on successful execution, regulatory progress, and continued access to capital.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations